Invitrogen last week said in an SEC filing that Ben Bulkley, its senior vice president of commercial operations, and John Radak, its finance and principal accounting officer, will leave the company at the end of January.
 
Bulkley will be replaced by Bernd Brust, Invitrogen’s general manager and vice president of European operations. Brust will be responsible for sales strategies, customer relations, and identifying avenues for customer growth, the company said.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.